{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:40Z","timestamp":1787003800703,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T00:00:00Z","timestamp":1178582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1038\/sj.bjc.6603787","type":"journal-article","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T06:26:36Z","timestamp":1178605596000},"page":"1639-1643","source":"Crossref","is-referenced-by-count":29,"title":["A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group"],"prefix":"10.1038","volume":"96","author":[{"given":"S","family":"Pignata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Greggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Febbraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,5,8]]},"reference":[{"key":"BF6603787_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mdg112","volume":"14","author":"MS Aapro","year":"2003","unstructured":"Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB, European Organisation for Research Treatment of Cancer Gynaecological Cancer Group (2003) Doxorubicine versus doxorubicin and cisplatin in advanced endometrial cancer: definitive results by a randomized study (55872) of the EORTC gynecologic cancer group. Ann Oncol 14: 441\u2013448","journal-title":"Ann Oncol"},{"key":"BF6603787_CR2","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospect of evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748\u20131756","journal-title":"J Clin Oncol"},{"key":"BF6603787_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ygyno.2005.11.019","volume":"101","author":"MS Carey","year":"2006","unstructured":"Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T, Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group (2006) Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 101: 158\u2013167","journal-title":"Gynecol Oncol"},{"key":"BF6603787_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/annonc\/mdj032","volume":"17","author":"A du Bois","year":"2006","unstructured":"du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (2006) Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic malignancies: a phase I\/II study of the Arbeitgheimenshaft Gynaekologishe Onkologie Studiengruppe ovarialKarzinom (AGO-OVAR). Ann Oncol 17: 93\u201396","journal-title":"Ann Oncol"},{"key":"BF6603787_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/annonc\/mdl376","volume":"18","author":"JM Ferrero","year":"2007","unstructured":"Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E (2007) Second line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18: 263\u2013268","journal-title":"Ann Oncol"},{"key":"BF6603787_CR6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","volume":"22","author":"GF Fleming","year":"2004","unstructured":"Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT (2004) Randomized phase III study of cisplatin plus doxorubicin with or without paclitaxel and filgrastim in endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 22: 2159\u20132166","journal-title":"J Clin Oncol"},{"key":"BF6603787_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"BF6603787_CR8","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program: Common Toxicity Criteria Version 2.0 April 30, 1999 [ \n                    http:\/\/ctep.info.nih.gov\n                    \n                   ]"},{"key":"BF6603787_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/1471-2407-6-202","volume":"6","author":"S Pignata","year":"2006","unstructured":"Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F, MITO Investigators (2006) Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer 6: 202\u2013206","journal-title":"BMC Cancer"},{"key":"BF6603787_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ejca.2005.09.026","volume":"42","author":"NP Polyzos","year":"2006","unstructured":"Polyzos NP, Pavlidis N, Paraskevaidis E, Ioannidis JP (2006) Randomized evidence for chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer 42: 319\u2013326","journal-title":"Eur J Cancer"},{"key":"BF6603787_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A","volume":"91","author":"T Safra","year":"2001","unstructured":"Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A, Muggia FM (2001) Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Analysis of toxicities and predictor of outcome. Cancer 91: 90\u2013100","journal-title":"Cancer"},{"key":"BF6603787_CR12","first-page":"3743","volume":"56","author":"T Sakakibara","year":"1996","unstructured":"Sakakibara T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ, Bankert RB (1996) Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumors xenografts. Cancer Res 56: 3743\u20133746","journal-title":"Cancer Res"},{"key":"BF6603787_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1586\/14737140.4.4.679","volume":"4","author":"AD Santin","year":"2004","unstructured":"Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ (2004) Current treatment options for advanced endometrial cancer. Expert Rev Anticancer Ther 4: 679\u2013689","journal-title":"Expert Rev Anticancer Ther"},{"key":"BF6603787_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BF6603787_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.1994.12.7.1408","volume":"12","author":"JT Thigpen","year":"1994","unstructured":"Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C.A (1994) Randomize comparison of doxorubicin versus doxorubicin and cyclophosphamide in advanced or recurrent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 12: 1408\u20131414","journal-title":"J Clin Oncol"},{"key":"BF6603787_CR16","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1200\/JCO.2004.02.088","volume":"22","author":"JT Thigpen","year":"2004","unstructured":"Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S (2004) Phase III trial of doxorubicin with or without cisplatin: a Gynecologic Oncology Group study. J Clin Oncol 22: 3902\u20133908","journal-title":"J Clin Oncol"},{"issue":"12","key":"BF6603787_CR17","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1002\/1097-0142(19931215)72:12<3671::AID-CNCR2820721219>3.0.CO;2-U","volume":"72","author":"J Vaage","year":"1993","unstructured":"Vaage J, Donovan D, Mayhew E, Abra R, Huang A (1993) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72 (12): 3671\u20133675","journal-title":"Cancer"},{"key":"BF6603787_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/bjc.1997.84","volume":"75","author":"J Vaage","year":"1997","unstructured":"Vaage J, Donovan D, Uster P, Working P (1997) Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 75: 482\u2013486","journal-title":"Br J Cancer"},{"key":"BF6603787_CR19","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/1097-0142(20011101)92:9<2327::AID-CNCR1579>3.0.CO;2-6","volume":"92","author":"CF Verschraegen","year":"2001","unstructured":"Verschraegen CF, Kavanagh JJ, Loyer E, Bodurka-Bevers D, Kudelka AP, HU W, Vincent M, Nelson T, Levenback C (2001) Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 92: 2327\u20132333","journal-title":"Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603787.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603787","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603787.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:27:23Z","timestamp":1684398443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,8]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["BF6603787"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603787","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,8]]}}}